The Stay-Out-of-Jail Shot: How Johnson & Johnson Marketed Invega Sustenna on False Premises

NORMAN, Okla., (The Oklahoma Post) – September 17th, 2025

Robert F. Kennedy Jr. stands out as one of the few national figures willing to challenge the convergence of pharmaceutical power, compromised regulators, and selective science. His work exposes how industry money shapes medical outcomes; from the FDA’s dependence on corporate user fees to the quiet sidelining of physicians who question unsafe marketing campaigns. In the case of Invega Sustenna, Kennedy’s critique is not simply about one product; it is a broader demand that medicine serve patients rather than balance sheets.

Vaccines and psychotropic drugs may appear unrelated, yet both move through the same machinery of government and industry influence. Each is advanced through regulatory systems partly funded by the very companies under review. Each is supported by paid experts and selective data. And too often, both leave behind patients with injuries, lasting side effects, or lifelong dependency, with little acknowledgment or accountability. Instead of building public trust, this profit-driven cycle has deepened mistrust and left Americans trapped in a system where corporate narrative overrides medical truth.

The pharmaceutical model has perfected a kind of alchemy: doubt becomes certainty, uncertainty becomes profit, and side effects become new markets. Its most effective maneuver is not innovation but repackaging; reviving old compounds under new names, paired with new promises, and aimed at new audiences. No example is more telling than Johnson & Johnson’s Invega Sustenna, marketed as the “stay-out-of-jail shot.”

The central flaw is straightforward. Many doctors who conducted or endorsed studies on Invega Sustenna failed to disclose that a significant portion of their subjects were not living with schizophrenia at all. They were experiencing methamphetamine or other substance-induced psychosis. Misclassifying acute intoxication as chronic mental illness distorted the data and converted sedation into proof of efficacy.

This is not a minor scientific error. It is an ethical collapse. Once false assumptions enter the medical record, they harden into accepted fact for prosecutors, judges, insurers, and the press. The consequences are visible in the case of Peyton Moyer. At seventeen, autistic and vulnerable, he was supplied methamphetamine by an adult relative. His hallucinations were misread as schizophrenia. He was injected with Invega Sustenna, a drug never designed for such a presentation. His condition deteriorated, his freedom disappeared, and his future was treated as a failed clinical case turned criminal matter. The drug marketed as a safeguard against prison became the mechanism that led him there.

This is the backdrop for the analysis that follows: a system where regulatory capture replaces oversight, where physician payments replace independence, and where public-health campaigns double as marketing strategies. Invega Sustenna was not the product of healing, but of commerce developed to extend patents, supported by an agency financially bound to industry, and sold with the claim that the criminal justice system itself was a market to be served.

Industry Funding of the FDA and Regulatory Capture

Let us begin with the overseer, the Food and Drug Administration, an institution created to protect the public from corporate excess. In practice, the FDA is tied closely to the industry it regulates. Under the Prescription Drug User Fee Act, pharmaceutical companies pay the agency millions each time they submit a new drug application. By fiscal year 2022 those user fees totaled approximately 1.4 billion dollars and covered a large share of the FDA’s drug review budget. Critics from Public Citizen to independent scholars have pointed out the obvious conflict. The referee is paid by the team.

Johnson and Johnson’s subsidiary Janssen Pharmaceuticals benefited greatly from this system. Its line of paliperidone injections, including Invega Sustenna, Invega Trinza, and Invega Hafyera, passed through expedited reviews with little resistance. In January 2018 the FDA went even further. It granted an unprecedented label expansion for Invega Sustenna that allowed the company to advertise the drug as capable of delaying arrest or incarceration in patients with schizophrenia. The notion of a prescription doubling as a parole officer startled many ethicists. Yet the agency’s approval came with a substantial reward. The decision granted Johnson and Johnson three more years of market exclusivity, delaying the arrival of cheaper generics and securing billions in continued revenue.

This is regulatory capture at its most visible. Rather than demanding proof that the studies distinguished drug induced psychosis from schizophrenia, the FDA accepted a claim that tied psychiatry to the criminal justice system. Compliance was reframed as public safety rather than patient health. The financial gains went to Johnson and Johnson.

Payments to Doctors and Researchers

No empire sustains itself on regulatory indulgence alone. It must cultivate its prophets. In 2018, Janssen reported 22,636 payments totaling $2.04 million connected to Invega Sustenna—fees for consulting, speaking, meals, and travel. A nearly identical sum was spent on its sister product, Invega Trinza. ProPublica’s Dollars for Docs database records the breadth of these transactions: a constellation of physicians compensated to repeat, in white coats and soft tones, the virtues of compliance and stability.

The government itself has documented the darker side of these arrangements. In 2013, Johnson & Johnson paid $2.2 billion to resolve criminal and civil allegations that it paid kickbacks to physicians and the nation’s largest long-term care pharmacy to boost prescriptions of Risperdal and Invega. The Department of Justice declared it one of the largest healthcare fraud settlements in U.S. history. The sin was not simply greed; it was the deliberate promotion of drugs for uses not approved, in populations most vulnerable.

Among the luminaries enlisted was Dr. Henry Nasrallah, a respected psychiatrist who served as investigator and endorser of Invega Sustenna. Upon its FDA approval in 2009, he was quoted in company press materials extolling the shot as a “definitive monitoring tool” to ensure compliance. His praise lent legitimacy, his name lent weight. But legitimacy bought with stipends is no less fragile than the data it defends.

The crown jewel of Janssen’s research portfolio was the PRIDE trial—Paliperidone Palmitate Research in Demonstrating Effectiveness. Conducted with 450 patients who had recent histories of incarceration, it purported to show that the monthly injection delayed relapse and reduced arrests compared to daily oral medications. Published in 2015, its results became the foundation for the FDA’s “stay-out-of-jail” approval. But the trial’s design was suspect: no comparison to other injectable antipsychotics, a population riddled with substance abuse histories, and diagnoses that blurred the line between meth-induced psychosis and schizophrenia. Garbage in, gospel out.

The Marketing Machine

With the label secured, Johnson & Johnson launched its campaign. This was no timid effort—it was a historic first. Trade journals dubbed it a “stay-out-of-jail card.” Internal celebrations marked the FDA’s decision as a marketing triumph. The company could now tell physicians, payers, and policymakers that Invega Sustenna was not merely a treatment but a social safeguard.

The narrative was rehearsed and polished. Untreated, the company warned, people with serious mental illness are three times more likely to end up in jail than in a hospital. The criminal justice system has become the nation’s largest mental health provider. But here was a solution: a monthly injection that would ease fears of non-compliance, prevent relapse, and keep troubled souls from prison bars.

To humanize the message, Janssen produced video testimonials. In one, a woman named Tanara, previously incarcerated, speaks of her liberation: the shot freed her from worrying about missing pills, allowed her to keep a job, restored stability. Such stories are moving, but they also serve as advertising props, blurring the line between individual experience and universal proof.

The campaign also targeted payers. Though each injection cost between $400 and $2,000 depending on dose, consultants argued it was cheaper than hospitalizations or incarceration. “Incarceration is expensive, as are hospital stays,” one professor declared. “Why not use something that can decrease the frequency of both?” In 2016, before the new approval, Invega Sustenna and Trinza already grossed $2.2 billion globally. With a jail-avoidance claim in hand, the cash flow only deepened.

The precise marketing budget remains undisclosed. Janssen declined to answer inquiries. But the reach was undeniable: journal ads, conference presentations, digital content, policy briefings. The message was everywhere: compliance equals freedom, freedom equals this shot.

Advocacy Groups and Media

Every empire needs apostles beyond its payroll. Johnson & Johnson found them in advocacy groups. According to The Atlantic, Janssen offered free samples and financial support to organizations aimed at keeping the mentally ill out of jails. One prominent voice was the Treatment Advocacy Center (TAC), a nonprofit that pushes for easier civil commitment and mandatory outpatient treatment. TAC’s executive director John Snook was quoted saying schizophrenia is the only illness where one of the major side effects is jail time. The statement is clever, and it dovetails perfectly with Janssen’s marketing.

The lineage of TAC is instructive. It sprang from the National Alliance on Mental Illness (NAMI), itself a recipient of more than $2 million from Janssen in the late 1990s. Thus the echo chamber was established: industry funds nonprofit, nonprofit champions narrative, narrative justifies industry’s solution.

Journalists too played their part. The Marshall Project, a nonprofit newsroom dedicated to criminal justice, ran a widely circulated article about the FDA’s decision. It accurately noted the claim, the exclusivity perk, and quoted skeptics. But in disseminating the very phrase “keep people out of prison,” it amplified Johnson & Johnson’s message. The outlet has disclosed no financial ties to J&J, and indeed there is no evidence of direct payment. Yet the company benefited from earned media coverage that lent the campaign an aura of newsworthiness.

Other coverage in FiercePharma and The Atlantic reinforced the drama. The public came to know Invega Sustenna not as a mere drug, but as a talisman against incarceration. The marketing line had leapt from corporate memos into national conversation.

Invega’s Origins: From Risperdal to Sustenna

What, then, is this miracle? Strip away the branding and you find paliperidone, the active metabolite of risperidone. Risperdal, launched in the 1990s, was heralded as a breakthrough antipsychotic. It was also haunted by scandal: lawsuits over boys developing breasts, black-box warnings for elderly dementia patients, and billions in settlements for illegal marketing.

As Risperdal’s patents neared expiration, Janssen unveiled paliperidone as Invega—first as extended-release tablets in 2006, then as Invega Sustenna injections in 2009. The difference was delivery, not revolution. By patenting the metabolite and controlling the formulation, Johnson & Johnson secured new monopolies.

Risperdal Consta, a biweekly injectable, gave way to Sustenna’s monthly dose. Later came Trinza (three months) and Hafyera (six months). Each iteration promised greater convenience, each secured new exclusivity. When one line faced generic competition, another was introduced. In 2021, Janssen even discontinued the original Invega tablets, not for safety reasons but to control the market. The FDA confirmed there was no evidence of danger; it was a business decision. This is evergreening—stretching a single compound’s profit life through reformulations and rebranding.

Thus Invega Sustenna is not a new cure. It is Risperdal in fresh clothing, marketed with new promises, and tied to criminal justice outcomes that Risperdal never dared to claim.

Local Leaders in the Dark

Sheriffs and county commissioners who embrace Johnson & Johnson’s programs often do so without any meaningful grasp of the risks involved. They are briefed with glossy presentations about reduced recidivism and taxpayer savings but seldom with the black-box warnings, the withdrawal syndromes, or the violent rebounds that accompany long-acting antipsychotics. Most lack medical training and rely entirely on contracted doctors, many of whom themselves are under industry influence. In this vacuum of understanding, law enforcement officials become unwitting salesmen for a pharmaceutical campaign, championing a “solution” whose dangers they neither diagnose nor endure.

The Collapse of Oklahoma’s Mental Health System

Layered over this local ignorance is the broader failure of the Oklahoma Department of Mental Health and Substance Abuse Services. The agency is chronically underfunded, plagued by staffing shortages, and stretched thin across a state with some of the highest rates of mental illness in the country. Instead of building robust community programs that address substance abuse, trauma, and preventative care, the department has leaned on quick pharmaceutical fixes and private contracts. The result is a system where jails and prisons have become the largest mental health providers in Oklahoma, not because they are equipped to heal, but because every other part of the safety net has already unraveled.

Breaking the Cycle or Enshrining Government Dependence?

Permit me to guide you southward to Cleveland County, Oklahoma, where the Sheriff’s Office trumpeted with fanfare a program it styled as “Breaking the Cycle of Mental Illness and Incarceration.” At first glance, the promise is noble: more than half of the inmates at the county jail suffer from mental health challenges, many also homeless, and officials sought to end the revolving door of arrest, release, relapse, and return. The solution, they proclaimed, lay in long-acting injectable antipsychotics, chief among them Johnson & Johnson’s Invega Sustenna. Administered in two shots behind bars, then monthly after release, these injections are heralded as tickets to stability, safety, and a new life.

The announcement bore all the trappings of benevolence: no cost to taxpayers, fewer psychiatric emergencies, and restored dignity for those too often forgotten. Yet beneath the benevolent rhetoric lurks a harder truth. Each injection, worth some $3,500, is funded not by the people but by the very corporation whose marketing strategy has long equated compliance with redemption. Thus the jail becomes not merely a place of confinement but a theater for Johnson & Johnson’s carceral narrative, where the line between rehabilitation and revenue is blurred beyond recognition.

Worse still, these injections carry a darker legacy: violent rebounds when doses lapse or side effects overwhelm. Counties are not left merely to manage the fallout, they are compensated for it, their coffers swelled by the very chaos that these drugs were supposed to prevent. Dependence becomes profit, relapse becomes revenue, and tragedy is tallied as success.

In Cleveland County’s embrace of this program, one sees not the breaking of a cycle but the forging of a new one, dependency rebranded as dignity, violence disguised as care, and commerce enthroned as justice. What is proclaimed as liberation may, in fact, be little more than a gilded chain, fastening vulnerable men and women to a treatment regime whose true beneficiary is not the inmate but the balance sheet of a pharmaceutical empire.

The Human Cost

Behind every revenue chart stands a human ledger. Consider again Peyton Moyer. At 15 onward, autistic and vulnerable, he was given methamphetamine by an adult relative maternal uncle. His hallucinations were acute, his fear real: he believed his uncle would kill him. This was not schizophrenia. It was stimulant poisoning. The father, cut out by the same court, for trying to point out these troubling issues.

Yet in September 2020, at Summit Ridge Hospital, he was diagnosed with psychosis and injected with Invega Sustenna. No toxicology screen was documented, despite his repeated disclosures of meth use. Advantage Behavioral Health continued prescribing antipsychotics without addressing the substance-induced cause. No mandatory child abuse report was filed, though Georgia law required it.

The consequences were dire. Peyton developed neurological injury and long-term psychiatric disability. He cycled through jail, where records confirm his non-compliance due to side effects and persistent psychosis. On December 28, 2021, a tragic offense occurred, tethering him permanently to the criminal justice system. His story embodies the very flaw hidden in the studies: when drug-induced crises are mislabeled as chronic illness, treatment becomes punishment, and punishment becomes destiny.

And Peyton is not alone. Families across the country have watched as children suffering from substance exposure were locked into life-long treatment regimens, their underlying causes ignored, their legal fates sealed. Johnson & Johnson’s “stay-out-of-jail” campaign rings hollow when the very medication it markets becomes the bridge to incarceration.

Remedies and Call to Action

• First, diagnostic integrity. Trials must separate substance-induced psychosis from primary psychotic disorders. Toxicology at intake, washout periods, structured reassessment—without these, results are worthless. All family members, including non-full custodial parents must be notified.
• Second, transparency. Patient-level trial data should be released for independent review. Let others examine whether the cohorts were what they were claimed to be.
• Third, label repair. The incarceration claim should be suspended pending independent replication. Marketing cannot outpace method.
• Fourth, disclosure enforcement. Payments to physicians must be tied to authorship eligibility. If you are paid to speak, you cannot simultaneously design the trial that will enrich the sponsor.
• Fifth, pediatric and disability safeguards. Minors and cognitively impaired patients must receive abuse screenings, toxicology checks, and informed consent disclosures of all risks, including neuroleptic malignant syndrome and rhabdomyolysis. All family members, including non-full custodial parents must be notified.
• Sixth, mandatory reporting. Physicians who ignore statutory duties to report suspected abuse must face prosecution. The law is not advisory. All family members, including non-full custodial must be notified.

The tragedy of Invega Sustenna is not that it failed to sedate. It is that sedation was confused with salvation, that marketing was confused with science, and that incarceration was confused with treatment. Johnson and Johnson turned a metabolite into a monopoly, a shot into a slogan, and vulnerable patients into permanent clients. The FDA, dependent on user fees, enabled it. Physicians, eased by payments, cooperated. Advocacy groups, supported by grants, amplified the message. Journalists, attracted by novelty, carried it forward.

And the Peytons of the world paid the price.

Corrupted science is worse than no science at all because it cloaks harm in the appearance of healing. A society that accepts “stay out of jail” as a medical endpoint has already admitted that its hospitals are prisons and its prisons are hospitals. Without integrity in diagnosis, regulation, and ethics, methamphetamine induced psychosis will continue to be mislabeled as lifelong schizophrenia, and profit will continue to be mistaken for salvation.

Invega Sustenna may silence chaos, but it cannot cleanse corruption. A treatment built on misclassification is not a treatment. It is marketing. And marketing, unlike medicine, cannot cure.

Dr. Jae H. Pak, practicing in both Minnesota and Georgia, is named in a criminal referral for his treatment of Peyton Moyer. According to that referral, Dr. Pak administered Invega Sustenna to a seventeen year old autistic minor who had already reported methamphetamine exposure from an uncle. Instead of ordering toxicology screens or filing a mandatory child abuse report, as Georgia law requires, Dr. Pak diagnosed psychosis as schizophrenia and placed Peyton on a permanent antipsychotic regimen. This failure to recognize substance induced psychosis, combined with the omission of mandatory reporting, compounded harm and set in motion devastating consequences.

Other physicians can avoid repeating this misconduct by ruling out drug induced causes before assigning a psychiatric diagnosis, by following mandatory reporting laws when abuse is disclosed, and by ensuring that informed consent is obtained before prescribing high risk psychotropics to vulnerable minors.

Compliance Checklist for Physicians Treating Minors with Suspected Psychosis

• Toxicology First: Always perform drug screens to rule out substance-induced psychosis before diagnosing schizophrenia or other primary psychiatric disorders.
• Mandatory Reporting: If a minor discloses drug use supplied by an adult, file a child abuse/neglect report immediately as required by law.
• Differential Diagnosis: Document a clear rationale distinguishing between stimulant-induced psychosis and chronic mental illness.
• Informed Consent: Obtain and record full informed consent, including risks of neuroleptic malignant syndrome, metabolic side effects, and long-term dependency.
• Developmental Considerations: Account for autism spectrum disorder, cognitive impairment, or other vulnerabilities before prescribing high-risk antipsychotics.
• Least-Restrictive Care: Prioritize interventions that address root causes (e.g., substance abuse treatment, family interventions) before resorting to life-long pharmacologic regimens.
• Continuous Monitoring: Reassess regularly for improvement, side effects, and appropriateness of continued treatment; adjust or discontinue if risks outweigh benefits.
• Inform all family members. Dads and moms ultimately know best, and must be in the loop.

Kennedy’s message is straightforward. When profits dictate diagnoses, when regulators see themselves as partners rather than watchdogs, and when vulnerable patients are turned into marketing props, justice itself is undermined. The story of Invega Sustenna, built on misclassified patients and reinforced by carceral marketing, shows exactly what he seeks to change. His fight is not against a single drug or a single company. It is against a culture of malpractice and corruption that leaves families like Peyton Moyer’s in ruin. If reform is to come it will require the relentless pursuit of accountability that Kennedy demands, rooting out corruption, insisting on transparency, and restoring medicine to its only legitimate purpose: healing.

Sources:

• Carome, M. (2022). Outrage of the Month: FDA-Corrupting User Fees Reauthorized. Public Citizen citizen.orgcitizen.org.
• Weintraub, A. (2018). J&J’s stay-out-of-jail marketing plan for Invega Sustenna raises eyebrows. FiercePharma fiercepharma.comfiercepharma.com.
• Eldridge, T. E. (2018). A Drug Company Says This Shot Will Keep You Out of Prison. The Marshall Project/Daily Beast themarshallproject.orgthemarshallproject.org.
• Bond, M. (2019). Marketing Psychiatric Drugs to Jailers and Judges. The Atlantic theatlantic.comtheatlantic.com.
• ProPublica Dollars for Docs (2019). Janssen Pharmaceuticals – Payments in 2018projects.propublica.org.
• U.S. Department of Justice (2013). Press Release: J&J to Pay $2.2 Billion for Risperdal, Invegajustice.gov.
• Waknine, Y. (2009). FDA Approves Once-Monthly Paliperidone Injection. Medscape Medical News medscape.com.
• Alphs, L. et al. (2015). Paliperidone Palmitate vs. Daily Orals in Schizophrenia (PRIDE Study). J. Clin. Psychiatry, 76(5):554-61 pubmed.ncbi.nlm.nih.gov.
• Marshall Project (2024). List of Major Donors (no J&J funding noted)themarshallproject.org.
• Beder, S. (2019). Pharmaceutical Industry Agenda Setting in Mental Health (NAMI funding info)herinst.org.
• Janssen Medical Info. (2025). Paliperidone is active metabolite of risperidonejnjmedicalconnect.com.
• FDA Notice (2024). Discontinuation of Invega (paliperidone) 1.5mg tabletspublic-inspection.federalregister.govpublic-inspection.federalregister.gov.

Writing By: King Shultz | Editing by Robbie Robertson

Got evidence, events, birthdays, obits or inside info?
Email The Oklahoma Post confidentially: editor@theokpost.com

And for the record: unlike the courthouse clique, The Oklahoma Post runs on facts, not dark money.

© 2025 The Oklahoma Post |

By The People’s Popular Paper | Oklahoma Special Report

2025 -The Oklahoma Post – TheOKPost.com is dedicated to delivering relevant news and information to Oklahomans, sharing their stories, pictures, and experiences. The content on this website includes contributions from various individuals and links to external public and privately owned sources. The views and opinions expressed in user-generated content are solely those of the respective authors and do not necessarily reflect The Oklahoma Post. The Oklahoma Post does not independently verify the accuracy of third-party contributions and rely upon contributors to fact-check their work. By sharing links and allowing open contributions, TheOKPost.com exercises the right to free speech and providing a platform for diverse perspectives.